These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15182793)

  • 1. Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy.
    Bouée S; Charlemagne A; Fagnani F; Le Jeunne P; Sermet C; Naudin F; Lancry PJ
    Joint Bone Spine; 2004 May; 71(3):214-20. PubMed ID: 15182793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice.
    Cutts C; LaCaze A; Tett S
    Br J Clin Pharmacol; 2002 Nov; 54(5):522-7. PubMed ID: 12445032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
    Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
    Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of cardiorenal risk factors in patients prescribed nonsteroidal anti-inflammatory drugs: data from managed care.
    Harley C; Wagner S
    Clin Ther; 2003 Jan; 25(1):139-49. PubMed ID: 12637116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model analysis of costs of blood pressure destabilization and edema associated with rofecoxib and celecoxib among older patients with osteoarthritis and hypertension in a Medicare Choice population.
    Becker RV; Burke TA; McCoy MA; Trotter JP
    Clin Ther; 2003 Feb; 25(2):647-62. PubMed ID: 12749519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
    Spiegel BM; Targownik L; Dulai GS; Gralnek IM
    Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of cyclooxygenase 2 inhibitor use in patients admitted to a large teaching hospital.
    Landsberg PG; Pillans PI; Radford JM
    Intern Med J; 2003; 33(5-6):225-8. PubMed ID: 12752891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial.
    Geba GP; Weaver AL; Polis AB; Dixon ME; Schnitzer TJ;
    JAMA; 2002 Jan; 287(1):64-71. PubMed ID: 11754710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
    [No Abstract]   [Full Text] [Related]  

  • 16. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database.
    Zhao SZ; Reynolds MW; Lejkowith J; Whelton A; Arellano FM
    Clin Ther; 2001 Sep; 23(9):1478-91. PubMed ID: 11589261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NSAIDs: gastroprotection or selective COX-2 inhibitor?
    Dickman A; Ellershaw J
    Palliat Med; 2004 May; 18(4):275-86. PubMed ID: 15198117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
    Peretz A
    Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.